BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 19770760)

  • 21. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.
    Vogelbaum MA; Jost S; Aghi MK; Heimberger AB; Sampson JH; Wen PY; Macdonald DR; Van den Bent MJ; Chang SM
    Neurosurgery; 2012 Jan; 70(1):234-43; discussion 243-4. PubMed ID: 21593697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
    Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
    Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas.
    Youssef G; Wen PY
    Curr Neurol Neurosci Rep; 2024 Feb; 24(2):17-25. PubMed ID: 38170429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
    Sipos L; Vitanovics D; Afra D
    Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glioma therapy in adults.
    Norden AD; Wen PY
    Neurologist; 2006 Nov; 12(6):279-92. PubMed ID: 17122724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging of the Posttherapeutic Brain.
    Telles BA; D'Amore F; Lerner A; Law M; Shiroishi MS
    Top Magn Reson Imaging; 2015 Jun; 24(3):147-54. PubMed ID: 26049818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
    Ellingson BM; Wen PY; Cloughesy TF
    Neurotherapeutics; 2017 Apr; 14(2):307-320. PubMed ID: 28108885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
    Shiroishi MS; Boxerman JL; Pope WB
    Neuro Oncol; 2016 Apr; 18(4):467-78. PubMed ID: 26364321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pros and cons of current brain tumor imaging.
    Ellingson BM; Wen PY; van den Bent MJ; Cloughesy TF
    Neuro Oncol; 2014 Oct; 16 Suppl 7(Suppl 7):vii2-11. PubMed ID: 25313235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pseudoprogression after glioma therapy: a comprehensive review.
    Kruser TJ; Mehta MP; Robins HI
    Expert Rev Neurother; 2013 Apr; 13(4):389-403. PubMed ID: 23545054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advanced MRI Techniques in the Monitoring of Treatment of Gliomas.
    Hyare H; Thust S; Rees J
    Curr Treat Options Neurol; 2017 Mar; 19(3):11. PubMed ID: 28349351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endpoints for clinical trials and revised assessment in neuro-oncology.
    Butowski N; Chang SM
    Curr Opin Neurol; 2012 Dec; 25(6):780-5. PubMed ID: 23007010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neuroradiological response criteria for malignant gliomas].
    Bendszus M; Platten M
    Nervenarzt; 2010 Aug; 81(8):950-5. PubMed ID: 20669003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiology: criteria for determining response to treatment and recurrence of high-grade gliomas.
    Lucas J; Zada G
    Neurosurg Clin N Am; 2012 Apr; 23(2):269-76, viii. PubMed ID: 22440870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroradiological response criteria for high-grade gliomas.
    Lutz K; Radbruch A; Wiestler B; Bäumer P; Wick W; Bendszus M
    Clin Neuroradiol; 2011 Nov; 21(4):199-205. PubMed ID: 21681688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Update on cerebral tumors].
    Benouaich-Amiel A; Delattre JY
    Bull Cancer; 2006 Jan; 93(1):73-81. PubMed ID: 16455509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pattern of care of high-grade gliomas].
    Laigle-Donadey F; Sanson M
    Rev Prat; 2006 Oct; 56(16):1779-86. PubMed ID: 17315503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response assessment in neuro-oncology.
    Quant EC; Wen PY
    Curr Oncol Rep; 2011 Feb; 13(1):50-6. PubMed ID: 21086192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic advances in malignant glioma: current status and future prospects.
    Robins HI; Lassman AB; Khuntia D
    Neuroimaging Clin N Am; 2009 Nov; 19(4):647-56. PubMed ID: 19959010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.